Matthew J. Sale

发表

Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction

S. Cook, K. Balmanno, Matthew J. Sale, 2019, Cancer drug resistance.

RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity

D. Esposito, F. McCormick, M. Trnka, 2021, Proceedings of the National Academy of Sciences.

Ras-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy

F. McCormick, M. Swain, A. Stephen, 2022, bioRxiv.

The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.

S. Cook, Matthew J. Sale, 2014, The Biochemical journal.

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

S. Cook, J. Dry, Paul D. Smith, 2019, Nature Communications.

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

S. Cook, Paul D. Smith, C. Caunt, 2015, Nature Reviews Cancer.

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

M. Garnett, J. Armenia, A. Lau, 2020, British Journal of Cancer.

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

S. Cook, Matthew J. Sale, 2013, British journal of pharmacology.

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

P. Edwards, S. Cook, J. Dry, 2011, Science Signaling.

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

S. Cook, Paul D. Smith, S. Guichard, 2014, Journal of Cell Science.

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

D. Adams, J. Saez-Rodriguez, R. McIntyre, 2019, Nature Communications.

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.

S. Cook, Paul D. Smith, K. Balmanno, 2012, Biochemical Society transactions.

Resistance to ERK 1 / 2 pathway inhibitors ; sweet spots , fitness deficits and drug addiction

S. Cook, K. Balmanno, Matthew J. Sale, 2019 .

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.

S. Cook, Matthew J. Sale, 2014, Biochemical Society transactions.

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

S. Cook, Matthew J. Sale, 2013, The Biochemical journal.

Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling

S. Cook, Rebecca H. Gilley, K. Stuart, 2017, The FEBS journal.

Lysine Acetylation Controls Local Protein Conformation by Influencing Proline Isomerization

J. Mellor, Françoise S Howe, David Clynes, 2014, Molecular cell.

The ribosomal S6 kinase 2 (RSK2)–SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling

F. McCormick, P. Castel, D. Simanshu, 2023, The Journal of biological chemistry.

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

D. Adams, J. Sáez-Rodríguez, R. McIntyre, 2019, Nature Communications.

RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy

F. McCormick, M. Swain, A. Stephen, 2023, Science advances.